Frequently Asked Questions

RTX-240 and the Cancer Clinical Trial

How is RTX-240 designed to work?

  • The ultimate goal in developing RTX-240 is to provide patients a safe and effective new cancer treatment option.
  • RTX-240 is an investigational cellular therapy designed to activate the immune system to fight cancer.

What is the purpose of this clinical trial?

The purpose of the clinical trial is to find out whether RTX-240 is safe, how much RTX-240 needs to be given for it to be effective and how often it should be given to be effective.

What type of solid tumors are included in the Phase 1/2 clinical study?

Examples of solid tumors include, but are not limited to, breast cancer, kidney cancer, melanoma, non-small cell lung cancer, small cell lung cancer, squamous cell cancer and more.

How is RTX-240 given to patients?

RTX-240 is given intravenously (IV), which means into a vein by a trained medical professional.

Do I have to undergo any preparation before receiving RTX-240?

Participants who join the trial will have a doctor’s exam, blood tests and additional lab work before receiving RTX-240.

What happens after RTX-240 is given?

  • Once participants receive the first dose of RTX-240, they will be closely observed and continue to be monitored over the treatment period until disease progression or undesirable toxicities.
  • After the last dose of RTX-240, the patient will participate in an end-of-treatment visit within 30 days of the last dose given.
  • Following the conclusion of study participation, patients will be monitored for up to 15 years for any potential incidence of long-term effects of RTX-240.
  • Long-term follow up assessments will occur every 30 days for the first two months and then annually thereafter.

Can I continue receiving any other anti-cancer therapies while on this trial?

  • Patients cannot receive other investigational anti-cancer treatments while receiving doses of RTX-240.
  • Once the final dose has been administered and the end of treatment visit has taken place, patients may go on to receive additional anti-cancer treatments.
  • Please speak with your doctor about any questions.

Will I be eligible for other trials if I choose to participate?

  • Although participants cannot be enrolled in other clinical trials while participating in the RTX-240 clinical trial, we do not anticipate that participation in the RTX-240 clinical trial will disqualify you from taking part in other future clinical trials.
  • It is important to note, however, that each trial has its own criteria regarding who can participate. Patients who participate in the Phase 1/2 trial for RTX-240 may also be able to participate in future RTX-240 trials, pending results of this trial.
  • Please speak with your doctor about any questions.

Does Rubius plan to open additional clinical trials for cancer?

  • Rubius Therapeutics plans to investigate RTX-240 in specific types of cancers that will be determined by the results of the Phase 1 portion of the RTX-240 clinical trial.
  • Additionally, Rubius Therapeutics is evaluating RTX-240 in relapsed and refractory acute myeloid leukemia.

Does Rubius offer any financial assistance for trial participation?

All necessary travel and lodging costs related to trial participation will be covered by Rubius Therapeutics; the process for patient reimbursement may vary by trial site.

What precautions will be taken to minimize risk of COVID-19 transmission to patients who decide to participate in the trial?

Rubius Therapeutics is committed to the safety of all clinicians and patients participating in the trial. Each trial site has its own procedures to minimize risk of COVID-19 transmission. If you have any questions, please speak directly with your physician.

For more information about the RTX-240 Phase 1/2 clinical trial, please visit clinicaltrials.gov or sign up below to receive more information about the RTX-240 trial.

RTX‑240 Phase 1/2 Clinical Trial

Complete a patient screener to see if you may be able to participate.

Patient Screener

Patient Screener

Sign up to learn more about Red Cell Therapeutics™ and cancer clinical trials.

Sign Up Form

Sign Up Form

Rubius Therapeutics is now enrolling patients in a phase 1/2 clinical trial of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors, or relapsed acute myeloid leukemia (AML) or refractory AML.

Complete a patient screener to see if you may be able to participate.

Thank you! You may be a potential candidate for a study doctor to evaluate for participation in this study.

If you wish to be connected to a clinical trial site in the RTX-240 study, please fill in your contact information below. Someone from our Patient Advocacy Team may reach out to you to determine your interest and if you would meet the requirements to be evaluated by a study doctor for screening in the RTX-240 study. Your personal information, including information entered below and discussed with our Patient Advocacy Team, may then be shared with a clinical study site.

NEXT

Thank you!

Based on the information provided, you may not meet the requirements for this study. We want to thank you for your interest – patient volunteers and their family members are an essential part of the development of new therapies for cancer. If you still would like to learn more about Red Cell Therapeutics™ and receive updates about clinical trials that might be available in your area for the potential treatment of cancer for yourself or a loved one, sign up here.

Thank you!

You may be a potential candidate for a study doctor to evaluate for participation in this study. If you wish to be connected to a clinical trial site for the RTX-240 study, please fill in your contact information below. Someone from our Patient Advocacy Team may reach out to you to determine if you would meet the requirements to be evaluated by a study doctor for screening for the RTX-240 study. Your personal information, including information entered below and discussed with our Patient Advocacy Team, may then be shared with a clinical study site.